{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T12:30:33Z","timestamp":1793449833204,"version":"4.5.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11914-025-00907-4","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T01:58:44Z","timestamp":1741312724000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Osteoporosis in Men: an Overlooked Patient Population"],"prefix":"10.1007","volume":"23","author":[{"given":"Sharon H.","family":"Chou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"issue":"8","key":"907_CR1","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s001980070064","volume":"11","author":"JA Kanis","year":"2000","unstructured":"Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, et al. Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int. 2000;11(8):669\u201374. https:\/\/doi.org\/10.1007\/s001980070064.","journal-title":"Osteoporos Int"},{"issue":"3","key":"907_CR2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1359\/jbmr.061113","volume":"22","author":"R Burge","year":"2007","unstructured":"Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the united States, 2005\u20132025. J Bone Min Res. 2007;22(3):465\u201375. https:\/\/doi.org\/10.1359\/jbmr.061113.","journal-title":"J Bone Min Res"},{"issue":"4","key":"907_CR3","doi-asserted-by":"publisher","first-page":"e0231374","DOI":"10.1371\/journal.pone.0231374","volume":"15","author":"FP Chou","year":"2020","unstructured":"Chou FP, Chang HC, Yeh CC, Wu CH, Cherng YG, Chen TL, et al. Sex differences in fracture outcomes within Taiwan population: A nationwide matched study. PLoS ONE. 2020;15(4):e0231374. https:\/\/doi.org\/10.1371\/journal.pone.0231374.","journal-title":"PLoS ONE"},{"issue":"1","key":"907_CR4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12891-021-03960-z","volume":"22","author":"JP Brown","year":"2021","unstructured":"Brown JP, Adachi JD, Schemitsch E, Tarride JE, Brown V, Bell A, et al. Mortality in older adults following a fragility fracture: real-world retrospective matched-cohort study in Ontario. BMC Musculoskelet Disord. 2021;22(1):105. https:\/\/doi.org\/10.1186\/s12891-021-03960-z.","journal-title":"BMC Musculoskelet Disord"},{"issue":"7","key":"907_CR5","doi-asserted-by":"publisher","first-page":"735","DOI":"10.18553\/jmcp.2017.23.7.735","volume":"23","author":"J Weaver","year":"2017","unstructured":"Weaver J, Sajjan S, Lewiecki EM, Harris ST. Diagnosis and treatment of osteoporosis before and after fracture: A Side-by-Side analysis of commercially insured and medicare advantage osteoporosis patients. J Manag Care Spec Pharm. 2017;23(7):735\u201344. https:\/\/doi.org\/10.18553\/jmcp.2017.23.7.735.","journal-title":"J Manag Care Spec Pharm"},{"issue":"24","key":"907_CR6","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1001\/jama.2018.7498","volume":"319","author":"USPST Force","year":"2018","unstructured":"Force USPST, Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, et al. Screening for osteoporosis to prevent fractures: US preventive services task force recommendation statement. JAMA. 2018;319(24):2521\u201331. https:\/\/doi.org\/10.1001\/jama.2018.7498.","journal-title":"JAMA"},{"key":"907_CR7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.27154","author":"USPST Force","year":"2025","unstructured":"Force USPST, Nicholson WK, Silverstein M, Wong JB, Chelmow D, Coker TR, et al. Screening for osteoporosis to prevent fractures: US preventive services task force recommendation statement. JAMA. 2025. https:\/\/doi.org\/10.1001\/jama.2024.27154.","journal-title":"JAMA"},{"issue":"10","key":"907_CR8","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1359\/jbmr.090419","volume":"24","author":"PM Cawthon","year":"2009","unstructured":"Cawthon PM, Ewing SK, McCulloch CE, Ensrud KE, Cauley JA, Cummings SR, et al. Loss of hip BMD in older men: the osteoporotic fractures in men (MrOS) study. J Bone Min Res. 2009;24(10):1728\u201335. https:\/\/doi.org\/10.1359\/jbmr.090419.","journal-title":"J Bone Min Res"},{"issue":"7","key":"907_CR9","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s00198-012-2226-0","volume":"24","author":"K Bleicher","year":"2013","unstructured":"Bleicher K, Cumming RG, Naganathan V, Seibel MJ, Blyth FM, Le Couteur DG, et al. Predictors of the rate of BMD loss in older men: findings from the CHAMP study. Osteoporos Int. 2013;24(7):1951\u201363. https:\/\/doi.org\/10.1007\/s00198-012-2226-0.","journal-title":"Osteoporos Int"},{"issue":"6","key":"907_CR10","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1210\/jc.2011-3045","volume":"97","author":"NB Watts","year":"2012","unstructured":"Watts NB, Adler RA, Bilezikian JP, Drake MT, Eastell R, Orwoll ES, et al. Osteoporosis in men: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(6):1802\u201322. https:\/\/doi.org\/10.1210\/jc.2011-3045.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"907_CR11","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","volume":"33","author":"MS LeBoff","year":"2022","unstructured":"LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, et al. The clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022;33(10):2049\u2013102. https:\/\/doi.org\/10.1007\/s00198-021-05900-y.","journal-title":"Osteoporos Int"},{"issue":"10","key":"907_CR12","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1002\/jbmr.2836","volume":"31","author":"JA Cauley","year":"2016","unstructured":"Cauley JA, Cawthon PM, Peters KE, Cummings SR, Ensrud KE, Bauer DC, et al. Risk factors for hip fracture in older men: the osteoporotic fractures in men study (MrOS). J Bone Min Res. 2016;31(10):1810\u20139. https:\/\/doi.org\/10.1002\/jbmr.2836.","journal-title":"J Bone Min Res"},{"issue":"6","key":"907_CR13","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1210\/jc.2011-3058","volume":"97","author":"MT Drake","year":"2012","unstructured":"Drake MT, Murad MH, Mauck KF, Lane MA, Undavalli C, Elraiyah T, et al. Clinical review. Risk factors for low bone mass-related fractures in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2012;97(6):1861\u201370. https:\/\/doi.org\/10.1210\/jc.2011-3058.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"907_CR14","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.1210\/jcem.87.8.8782","volume":"87","author":"D Mittan","year":"2002","unstructured":"Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder JM. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab. 2002;87(8):3656\u201361. https:\/\/doi.org\/10.1210\/jcem.87.8.8782.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"907_CR15","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMoa041943","volume":"352","author":"VB Shahinian","year":"2005","unstructured":"Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2):154\u201364. https:\/\/doi.org\/10.1056\/NEJMoa041943.","journal-title":"N Engl J Med"},{"issue":"6","key":"907_CR16","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1370\/afm.753","volume":"5","author":"AJ Shepherd","year":"2007","unstructured":"Shepherd AJ, Cass AR, Carlson CA, Ray L. Development and internal validation of the male osteoporosis risk Estimation score. Ann Fam Med. 2007;5(6):540\u20136. https:\/\/doi.org\/10.1370\/afm.753.","journal-title":"Ann Fam Med"},{"key":"907_CR17","unstructured":"Sagalla N, Alexopoulos AS, Gordon AM, Ear B, Nwankwo VC, Mystakelis HA et al. Screening for Male Osteoporosis: A Systematic Review. VA Evidence-based Synthesis Program Reports. Washington (DC)2022."},{"issue":"11","key":"907_CR18","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1007\/s40618-023-02082-8","volume":"46","author":"G Adami","year":"2023","unstructured":"Adami G, Biffi A, Porcu G, Ronco R, Alvaro R, Bogini R, et al. A systematic review on the performance of fracture risk assessment tools: FRAX, DeFRA, FRA-HS. J Endocrinol Invest. 2023;46(11):2287\u201397. https:\/\/doi.org\/10.1007\/s40618-023-02082-8.","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"907_CR19","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1001\/jama.285.6.785","volume":"285","author":"Nih Consensus Development Panel on Osteoporosis Prevention D, Therapy","year":"2001","unstructured":"Nih Consensus Development Panel on Osteoporosis Prevention D, Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285(6):785\u201395. https:\/\/doi.org\/10.1001\/jama.285.6.785.","journal-title":"JAMA"},{"issue":"5","key":"907_CR20","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s00198-014-2655-z","volume":"25","author":"ES Siris","year":"2014","unstructured":"Siris ES, Adler R, Bilezikian J, Bolognese M, Dawson-Hughes B, Favus MJ, et al. The clinical diagnosis of osteoporosis: a position statement from the National bone health alliance working group. Osteoporos Int. 2014;25(5):1439\u201343. https:\/\/doi.org\/10.1007\/s00198-014-2655-z.","journal-title":"Osteoporos Int"},{"key":"907_CR21","first-page":"1","volume":"843","author":"Assessment of fracture risk","year":"1994","unstructured":"Assessment of fracture risk. And its application to screening for postmenopausal osteoporosis. Report of a WHO study group. World Health Organ Tech Rep Ser. 1994;843:1\u2013129.","journal-title":"World Health Organ Tech Rep Ser"},{"issue":"6","key":"907_CR22","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/BF01622200","volume":"4","author":"JA Kanis","year":"1994","unstructured":"Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO study group. Osteoporos Int. 1994;4(6):368\u201381. https:\/\/doi.org\/10.1007\/BF01622200.","journal-title":"Osteoporos Int"},{"issue":"1","key":"907_CR23","doi-asserted-by":"publisher","first-page":"101435","DOI":"10.1016\/j.jocd.2023.101435","volume":"27","author":"C Shuhart","year":"2024","unstructured":"Shuhart C, Cheung A, Gill R, Gani L, Goel H, Szalat A. Executive summary of the 2023 adult position development conference of the international society for clinical densitometry: DXA reporting, Follow-up BMD testing and trabecular bone score application and reporting. J Clin Densitom. 2024;27(1):101435. https:\/\/doi.org\/10.1016\/j.jocd.2023.101435.","journal-title":"J Clin Densitom"},{"issue":"11","key":"907_CR24","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1007\/s00198-011-1632-z","volume":"22","author":"JA Kanis","year":"2011","unstructured":"Kanis JA, Bianchi G, Bilezikian JP, Kaufman JM, Khosla S, Orwoll E, et al. Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos Int. 2011;22(11):2789\u201398. https:\/\/doi.org\/10.1007\/s00198-011-1632-z.","journal-title":"Osteoporos Int"},{"issue":"2","key":"907_CR25","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jocd.2013.09.008","volume":"17","author":"JT Schousboe","year":"2014","unstructured":"Schousboe JT, Tanner SB, Leslie WD. Definition of osteoporosis by bone density criteria in men: effect of using female instead of male young reference data depends on skeletal site and densitometer manufacturer. J Clin Densitom. 2014;17(2):301\u20136. https:\/\/doi.org\/10.1016\/j.jocd.2013.09.008.","journal-title":"J Clin Densitom"},{"issue":"1","key":"907_CR26","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1385\/jcd:5:1:087","volume":"5","author":"KG Faulkner","year":"2002","unstructured":"Faulkner KG, Orwoll E. Implications in the use of T-scores for the diagnosis of osteoporosis in men. J Clin Densitom. 2002;5(1):87\u201393. https:\/\/doi.org\/10.1385\/jcd:5:1:087.","journal-title":"J Clin Densitom"},{"issue":"4","key":"907_CR27","doi-asserted-by":"publisher","first-page":"461","DOI":"10.18553\/jmcp.2017.23.4.461","volume":"23","author":"J Weaver","year":"2017","unstructured":"Weaver J, Sajjan S, Lewiecki EM, Harris ST, Marvos P. Prevalence and cost of subsequent fractures among U.S. Patients with an incident fracture. J Manag Care Spec Pharm. 2017;23(4):461\u201371. https:\/\/doi.org\/10.18553\/jmcp.2017.23.4.461.","journal-title":"J Manag Care Spec Pharm"},{"issue":"6","key":"907_CR28","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s00198-019-05274-2","volume":"31","author":"WD Leslie","year":"2020","unstructured":"Leslie WD, Schousboe JT, Morin SN, Martineau P, Lix LM, Johansson H, et al. Fracture risk following high-trauma versus low-trauma fracture: a registry-based cohort study. Osteoporos Int. 2020;31(6):1059\u201367. https:\/\/doi.org\/10.1007\/s00198-019-05274-2.","journal-title":"Osteoporos Int"},{"issue":"5","key":"907_CR29","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1017\/S1368980011000565","volume":"14","author":"AC Ross","year":"2011","unstructured":"Ross AC. The 2011 report on dietary reference intakes for calcium and vitamin D. Public Health Nutr. 2011;14(5):938\u20139. https:\/\/doi.org\/10.1017\/S1368980011000565.","journal-title":"Public Health Nutr"},{"issue":"8","key":"907_CR30","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1210\/clinem\/dgae290","volume":"109","author":"MB Demay","year":"2024","unstructured":"Demay MB, Pittas AG, Bikle DD, Diab DL, Kiely ME, Lazaretti-Castro M, et al. Vitamin D for the prevention of disease: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2024;109(8):1907\u201347. https:\/\/doi.org\/10.1210\/clinem\/dgae290.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"907_CR31","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.amjmed.2003.12.029","volume":"116","author":"HA Bischoff-Ferrari","year":"2004","unstructured":"Bischoff-Ferrari HA, Dietrich T, Orav EJ, Dawson-Hughes B. Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med. 2004;116(9):634\u20139. https:\/\/doi.org\/10.1016\/j.amjmed.2003.12.029.","journal-title":"Am J Med"},{"issue":"3","key":"907_CR32","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1359\/JBMR.051206","volume":"21","author":"RM Daly","year":"2006","unstructured":"Daly RM, Brown M, Bass S, Kukuljan S, Nowson C. Calcium- and vitamin D3-fortified milk reduces bone loss at clinically relevant skeletal sites in older men: a 2-year randomized controlled trial. J Bone Min Res. 2006;21(3):397\u2013405. https:\/\/doi.org\/10.1359\/JBMR.051206.","journal-title":"J Bone Min Res"},{"issue":"10","key":"907_CR33","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1056\/NEJM199709043371003","volume":"337","author":"B Dawson-Hughes","year":"1997","unstructured":"Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 1997;337(10):670\u20136. https:\/\/doi.org\/10.1056\/NEJM199709043371003.","journal-title":"N Engl J Med"},{"issue":"4","key":"907_CR34","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1210\/jc.2010-2284","volume":"96","author":"S Kukuljan","year":"2011","unstructured":"Kukuljan S, Nowson CA, Sanders KM, Nicholson GC, Seibel MJ, Salmon J, et al. Independent and combined effects of calcium-vitamin D3 and exercise on bone structure and strength in older men: an 18-month factorial design randomized controlled trial. J Clin Endocrinol Metab. 2011;96(4):955\u201363. https:\/\/doi.org\/10.1210\/jc.2010-2284.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"907_CR35","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/jbmr.4008","volume":"35","author":"AT Harding","year":"2020","unstructured":"Harding AT, Weeks BK, Lambert C, Watson SL, Weis LJ, Beck BR. A comparison of Bone-Targeted exercise strategies to reduce fracture risk in Middle-Aged and older men with osteopenia and osteoporosis: LIFTMOR-M Semi-Randomized controlled trial. J Bone Min Res. 2020;35(8):1404\u201314. https:\/\/doi.org\/10.1002\/jbmr.4008.","journal-title":"J Bone Min Res"},{"issue":"12","key":"907_CR36","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1002\/art.42646","volume":"75","author":"MB Humphrey","year":"2023","unstructured":"Humphrey MB, Russell L, Danila MI, Fink HA, Guyatt G, Cannon M, et al. 2022 American college of rheumatology guideline for the prevention and treatment of Glucocorticoid-Induced osteoporosis. Arthritis Rheumatol. 2023;75(12):2088\u2013102. https:\/\/doi.org\/10.1002\/art.42646.","journal-title":"Arthritis Rheumatol"},{"issue":"15","key":"907_CR37","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1200\/JCO.19.03148","volume":"38","author":"PJ Saylor","year":"2020","unstructured":"Saylor PJ, Rumble RB, Tagawa S, Eastham JA, Finelli A, Reddy PS, et al. Bone health and Bone-Targeted therapies for prostate cancer: ASCO endorsement of a Cancer care Ontario guideline. J Clin Oncol. 2020;38(15):1736\u201343. https:\/\/doi.org\/10.1200\/JCO.19.03148.","journal-title":"J Clin Oncol"},{"key":"907_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jbo.2017.03.001","volume":"7","author":"P Hadji","year":"2017","unstructured":"Hadji P, Aapro MS, Body JJ, Gnant M, Brandi ML, Reginster JY, et al. Management of aromatase Inhibitor-Associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol. 2017;7:1\u201312. https:\/\/doi.org\/10.1016\/j.jbo.2017.03.001.","journal-title":"J Bone Oncol"},{"issue":"9","key":"907_CR39","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1007\/s40520-023-02478-9","volume":"35","author":"C Beaudart","year":"2023","unstructured":"Beaudart C, Demonceau C, Sabico S, Veronese N, Cooper C, Harvey N, et al. Efficacy of osteoporosis Pharmacological treatments in men: a systematic review and meta-analysis. Aging Clin Exp Res. 2023;35(9):1789\u2013806. https:\/\/doi.org\/10.1007\/s40520-023-02478-9.","journal-title":"Aging Clin Exp Res"},{"issue":"18","key":"907_CR40","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357(18):1799\u2013809. https:\/\/doi.org\/10.1056\/NEJMoa074941.","journal-title":"N Engl J Med"},{"issue":"18","key":"907_CR41","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1056\/NEJMoa1204061","volume":"367","author":"S Boonen","year":"2012","unstructured":"Boonen S, Reginster JY, Kaufman JM, Lippuner K, Zanchetta J, Langdahl B, et al. Fracture risk and Zoledronic acid therapy in men with osteoporosis. N Engl J Med. 2012;367(18):1714\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1204061.","journal-title":"N Engl J Med"},{"issue":"18","key":"907_CR42","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly Zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809\u201322. https:\/\/doi.org\/10.1056\/NEJMoa067312.","journal-title":"N Engl J Med"},{"issue":"25","key":"907_CR43","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","volume":"379","author":"IR Reid","year":"2018","unstructured":"Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Wong S, et al. Fracture prevention with zoledronate in older women with osteopenia. N Engl J Med. 2018;379(25):2407\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1808082.","journal-title":"N Engl J Med"},{"issue":"5","key":"907_CR44","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","volume":"80","author":"SL Ruggiero","year":"2022","unstructured":"Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American association of oral and maxillofacial surgeons\u2019 position paper on Medication-Related osteonecrosis of the Jaws-2022 update. J Oral Maxillofac Surg. 2022;80(5):920\u201343. https:\/\/doi.org\/10.1016\/j.joms.2022.02.008.","journal-title":"J Oral Maxillofac Surg"},{"issue":"1","key":"907_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbmr.1998","volume":"29","author":"E Shane","year":"2014","unstructured":"Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American society for bone and mineral research. J Bone Min Res. 2014;29(1):1\u201323. https:\/\/doi.org\/10.1002\/jbmr.1998.","journal-title":"J Bone Min Res"},{"issue":"8","key":"907_CR46","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1056\/NEJMoa1916525","volume":"383","author":"DM Black","year":"2020","unstructured":"Black DM, Geiger EJ, Eastell R, Vittinghoff E, Li BH, Ryan DS, et al. Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. N Engl J Med. 2020;383(8):743\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1916525.","journal-title":"N Engl J Med"},{"issue":"1","key":"907_CR47","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3109\/17453674.2015.1004149","volume":"86","author":"J Schilcher","year":"2015","unstructured":"Schilcher J, Koeppen V, Aspenberg P, Michaelsson K. Risk of atypical femoral fracture during and after bisphosphonate use. Acta Orthop. 2015;86(1):100\u20137. https:\/\/doi.org\/10.3109\/17453674.2015.1004149.","journal-title":"Acta Orthop"},{"issue":"2","key":"907_CR48","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1210\/er.2018-00001","volume":"40","author":"DM Black","year":"2019","unstructured":"Black DM, Abrahamsen B, Bouxsein ML, Einhorn T, Napoli N. Atypical femur fractures: review of epidemiology, relationship to bisphosphonates, prevention, and clinical management. Endocr Rev. 2019;40(2):333\u201368. https:\/\/doi.org\/10.1210\/er.2018-00001.","journal-title":"Endocr Rev"},{"issue":"24","key":"907_CR49","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"DM Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial Long-term extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927\u201338. https:\/\/doi.org\/10.1001\/jama.296.24.2927.","journal-title":"JAMA"},{"issue":"2","key":"907_CR50","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/jbmr.1494","volume":"27","author":"DM Black","year":"2012","unstructured":"Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, et al. The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal fracture trial (PFT). J Bone Min Res. 2012;27(2):243\u201354. https:\/\/doi.org\/10.1002\/jbmr.1494.","journal-title":"J Bone Min Res"},{"issue":"5","key":"907_CR51","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/jbmr.11","volume":"25","author":"AV Schwartz","year":"2010","unstructured":"Schwartz AV, Bauer DC, Cummings SR, Cauley JA, Ensrud KE, Palermo L, et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Min Res. 2010;25(5):976\u201382. https:\/\/doi.org\/10.1002\/jbmr.11.","journal-title":"J Bone Min Res"},{"issue":"12","key":"907_CR52","doi-asserted-by":"publisher","first-page":"4546","DOI":"10.1210\/jc.2014-1971","volume":"99","author":"F Cosman","year":"2014","unstructured":"Cosman F, Cauley JA, Eastell R, Boonen S, Palermo L, Reid IR, et al. Reassessment of fracture risk in women after 3 years of treatment with Zoledronic acid: when is it reasonable to discontinue treatment? J Clin Endocrinol Metab. 2014;99(12):4546\u201354. https:\/\/doi.org\/10.1210\/jc.2014-1971.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"907_CR53","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/jbmr.2708","volume":"31","author":"RA Adler","year":"2016","unstructured":"Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, et al. Managing osteoporosis in patients on Long-Term bisphosphonate treatment: report of a task force of the American society for bone and mineral research. J Bone Min Res. 2016;31(1):16\u201335. https:\/\/doi.org\/10.1002\/jbmr.2708.","journal-title":"J Bone Min Res"},{"issue":"9","key":"907_CR54","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1210\/jc.2012-1569","volume":"97","author":"E Orwoll","year":"2012","unstructured":"Orwoll E, Teglbjaerg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler DL, et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab. 2012;97(9):3161\u20139. https:\/\/doi.org\/10.1210\/jc.2012-1569.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"907_CR55","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756\u201365. https:\/\/doi.org\/10.1056\/NEJMoa0809493.","journal-title":"N Engl J Med"},{"issue":"4","key":"907_CR56","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1210\/jc.2014-4079","volume":"100","author":"BL Langdahl","year":"2015","unstructured":"Langdahl BL, Teglbjaerg CS, Ho PR, Chapurlat R, Czerwinski E, Kendler DL, et al. A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. J Clin Endocrinol Metab. 2015;100(4):1335\u201342. https:\/\/doi.org\/10.1210\/jc.2014-4079.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"907_CR57","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJMoa0809003","volume":"361","author":"MR Smith","year":"2009","unstructured":"Smith MR, Egerdie B, Hernandez Toriz N, Feldman R, Tammela TL, Saad F, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009;361(8):745\u201355. https:\/\/doi.org\/10.1056\/NEJMoa0809003.","journal-title":"N Engl J Med"},{"issue":"4","key":"907_CR58","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011;96(4):972\u201380. https:\/\/doi.org\/10.1210\/jc.2010-1502.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"907_CR59","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2018","unstructured":"Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M, et al. Vertebral fractures after discontinuation of denosumab: A post hoc analysis of the randomized Placebo-Controlled FREEDOM trial and its extension. J Bone Min Res. 2018;33(2):190\u20138. https:\/\/doi.org\/10.1002\/jbmr.3337.","journal-title":"J Bone Min Res"},{"issue":"7","key":"907_CR60","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, et al. 10 Years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513\u201323. https:\/\/doi.org\/10.1016\/S2213-8587(17)30138-9.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"907_CR61","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","volume":"18","author":"ES Orwoll","year":"2003","unstructured":"Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, et al. The effect of teriparatide [human parathyroid hormone (1\u201334)] therapy on bone density in men with osteoporosis. J Bone Min Res. 2003;18(1):9\u201317. https:\/\/doi.org\/10.1359\/jbmr.2003.18.1.9.","journal-title":"J Bone Min Res"},{"issue":"5","key":"907_CR62","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s00198-004-1713-3","volume":"16","author":"JM Kaufman","year":"2005","unstructured":"Kaufman JM, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky GP, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int. 2005;16(5):510\u20136. https:\/\/doi.org\/10.1007\/s00198-004-1713-3.","journal-title":"Osteoporos Int"},{"issue":"12","key":"907_CR63","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1002\/jbmr.4719","volume":"37","author":"E Czerwinski","year":"2022","unstructured":"Czerwinski E, Cardona J, Plebanski R, Recknor C, Vokes T, Saag KG, et al. The efficacy and safety of Abaloparatide-SC in men with osteoporosis: A randomized clinical trial. J Bone Min Res. 2022;37(12):2435\u201342. https:\/\/doi.org\/10.1002\/jbmr.4719.","journal-title":"J Bone Min Res"},{"issue":"7","key":"907_CR64","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: A randomized clinical trial. JAMA. 2016;316(7):722\u201333. https:\/\/doi.org\/10.1001\/jama.2016.11136.","journal-title":"JAMA"},{"issue":"13","key":"907_CR65","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJMoa035725","volume":"349","author":"JS Finkelstein","year":"2003","unstructured":"Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003;349(13):1216\u201326. https:\/\/doi.org\/10.1056\/NEJMoa035725.","journal-title":"N Engl J Med"},{"issue":"6","key":"907_CR66","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1002\/jbmr.1870","volume":"28","author":"CC Gluer","year":"2013","unstructured":"Gluer CC, Marin F, Ringe JD, Hawkins F, Moricke R, Papaioannu N, et al. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J Bone Min Res. 2013;28(6):1355\u201368. https:\/\/doi.org\/10.1002\/jbmr.1870.","journal-title":"J Bone Min Res"},{"issue":"12","key":"907_CR67","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1007\/s00198-004-1636-z","volume":"15","author":"ES Kurland","year":"2004","unstructured":"Kurland ES, Heller SL, Diamond B, McMahon DJ, Cosman F, Bilezikian JP. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1\u201334)]. Osteoporos Int. 2004;15(12):992\u20137. https:\/\/doi.org\/10.1007\/s00198-004-1636-z.","journal-title":"Osteoporos Int"},{"issue":"9","key":"907_CR68","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1210\/jc.2017-02163","volume":"103","author":"EM Lewiecki","year":"2018","unstructured":"Lewiecki EM, Blicharski T, Goemaere S, Lippuner K, Meisner PD, Miller PD, et al. A phase III randomized Placebo-Controlled trial to evaluate efficacy and safety of Romosozumab in men with osteoporosis. J Clin Endocrinol Metab. 2018;103(9):3183\u201393. https:\/\/doi.org\/10.1210\/jc.2017-02163.","journal-title":"J Clin Endocrinol Metab"},{"issue":"16","key":"907_CR69","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532\u201343. https:\/\/doi.org\/10.1056\/NEJMoa1607948.","journal-title":"N Engl J Med"},{"issue":"4","key":"907_CR70","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/jamainternmed.2016.9539","volume":"177","author":"PJ Snyder","year":"2017","unstructured":"Snyder PJ, Kopperdahl DL, Stephens-Shields AJ, Ellenberg SS, Cauley JA, Ensrud KE, et al. Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: A controlled clinical trial. JAMA Intern Med. 2017;177(4):471\u20139. https:\/\/doi.org\/10.1001\/jamainternmed.2016.9539.","journal-title":"JAMA Intern Med"},{"issue":"6","key":"907_CR71","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1111\/andr.12901","volume":"8","author":"R Swerdloff","year":"2020","unstructured":"Swerdloff R, Wang C. Reflections on the T trials. Andrology. 2020;8(6):1512\u20138. https:\/\/doi.org\/10.1111\/andr.12901.","journal-title":"Andrology"},{"issue":"7","key":"907_CR72","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1001\/jama.2016.21043","volume":"317","author":"MJ Budoff","year":"2017","unstructured":"Budoff MJ, Ellenberg SS, Lewis CE, Mohler ER 3rd, Wenger NK, Bhasin S, et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA. 2017;317(7):708\u201316. https:\/\/doi.org\/10.1001\/jama.2016.21043.","journal-title":"JAMA"},{"issue":"1","key":"907_CR73","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S2213-8587(20)30367-3","volume":"9","author":"G Wittert","year":"2021","unstructured":"Wittert G, Bracken K, Robledo KP, Grossmann M, Yeap BB, Handelsman DJ, et al. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes Endocrinol. 2021;9(1):32\u201345. https:\/\/doi.org\/10.1016\/S2213-8587(20)30367-3.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"907_CR74","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa2215025","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, et al. Cardiovascular safety of Testosterone-Replacement therapy. N Engl J Med. 2023;389(2):107\u201317. https:\/\/doi.org\/10.1056\/NEJMoa2215025.","journal-title":"N Engl J Med"},{"issue":"3","key":"907_CR75","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa2308836","volume":"390","author":"PJ Snyder","year":"2024","unstructured":"Snyder PJ, Bauer DC, Ellenberg SS, Cauley JA, Buhr KA, Bhasin S, et al. Testosterone treatment and fractures in men with hypogonadism. N Engl J Med. 2024;390(3):203\u201311. https:\/\/doi.org\/10.1056\/NEJMoa2308836.","journal-title":"N Engl J Med"},{"issue":"3","key":"907_CR76","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1056\/NEJMe2313787","volume":"390","author":"M Grossmann","year":"2024","unstructured":"Grossmann M, Anawalt BD. Breaking News - Testosterone treatment and fractures in older men. N Engl J Med. 2024;390(3):267\u20138. https:\/\/doi.org\/10.1056\/NEJMe2313787.","journal-title":"N Engl J Med"},{"issue":"5","key":"907_CR77","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1210\/jc.2019-00192","volume":"104","author":"P Barrionuevo","year":"2019","unstructured":"Barrionuevo P, Kapoor E, Asi N, Alahdab F, Mohammed K, Benkhadra K, et al. Efficacy of Pharmacological therapies for the prevention of fractures in postmenopausal women: A network Meta-Analysis. J Clin Endocrinol Metab. 2019;104(5):1623\u201330. https:\/\/doi.org\/10.1210\/jc.2019-00192.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"907_CR78","doi-asserted-by":"publisher","first-page":"E14","DOI":"10.25011\/cim.v45i3.38875","volume":"45","author":"P Li","year":"2022","unstructured":"Li P, Wu X, Li Y, Huang J. Denosumab versus bisphosphonates for the prevention of the vertebral fractures in men with osteoporosis: an updated network Meta-Analysis. Clin Invest Med. 2022;45(3):E14\u201322. https:\/\/doi.org\/10.25011\/cim.v45i3.38875.","journal-title":"Clin Invest Med"},{"issue":"10","key":"907_CR79","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1093\/jbmr\/zjae090","volume":"39","author":"TM Keaveny","year":"2024","unstructured":"Keaveny TM, Adams AL, Orwoll ES, Khosla S, Siris ES, McClung MR, et al. Osteoporosis treatment prevents hip fracture similarly in both sexes: the FOCUS observational study. J Bone Min Res. 2024;39(10):1424\u201333. https:\/\/doi.org\/10.1093\/jbmr\/zjae090.","journal-title":"J Bone Min Res"},{"issue":"8","key":"907_CR80","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S2213-8587(20)30159-5","volume":"8","author":"DM Black","year":"2020","unstructured":"Black DM, Bauer DC, Vittinghoff E, Lui LY, Grauer A, Marin F, et al. Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials. Lancet Diabetes Endocrinol. 2020;8(8):672\u201382. https:\/\/doi.org\/10.1016\/S2213-8587(20)30159-5.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"907_CR81","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41584-024-01094-9","volume":"20","author":"NR Fuggle","year":"2024","unstructured":"Fuggle NR, Beaudart C, Bruyere O, Abrahamsen B, Al-Daghri N, Burlet N, et al. Evidence-Based guideline for the management of osteoporosis in men. Nat Rev Rheumatol. 2024;20(4):241\u201351. https:\/\/doi.org\/10.1038\/s41584-024-01094-9.","journal-title":"Nat Rev Rheumatol"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-025-00907-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11914-025-00907-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-025-00907-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:33:41Z","timestamp":1768473221000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11914-025-00907-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["907"],"URL":"https:\/\/doi.org\/10.1007\/s11914-025-00907-4","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,7]]},"assertion":[{"value":"17 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"13"}}